ClinicalTrials.gg
CompletedNCT04742907Updated Apr 16, 2025Results posted

Safety and Efficacy of TU-100 as an Adjunct to an Enhanced Recovery After Surgery in Subjects Undergoing Bowel Resection

A Phase 2 interventional study of TU-100 and Placebo in Enhanced Recovery After Surgery, sponsored by Tsumura USA. Completed at 36 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-16.

Sponsored by Tsumura USA · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
402
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This multicenter, randomized, double-blinded, placebo-controlled study will evaluate the effect of TU-100 on resolution of postoperative ileus (POI) in subjects undergoing open or laparoscopic bowel resection (BR).

Read the detailed description

Subjects will be screened up to 28 days before their planned surgery and will be randomized 1:1:1 (TU-100 15 g/day: TU-100 7.5 g/day: placebo) on postoperative Day 1 before the first dose of study medication. After randomization, subjects will receive a total daily dose of TU-100 15g, TU-100 7.5 g, or matching placebo (3 times per day (TID)) until hospital discharge or ≤ 10 days (whichever is earlier). All subjects will be treated with study medication as adjunct to an enhanced recovery (ERAS) pathway for gastrointestinal (GI) recovery.

02

Conditions studied

  • Enhanced Recovery After Surgery
03

In context

Lead sponsor

Tsumura USA is the lead sponsor of 10 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female ≥ 18 years of age
  2. Women of (WOCBP) or men whose sexual partners are WOCBP; must be able and willing to use at least 1 highly effective method of during the study and for 30 days after the last dose of study drug
  3. Physical Status Score of 1 to 3
  4. Scheduled for an elective BR via open or laparoscopic approach
  5. Ability to understand the study procedures, have agreed to participate in the study program, and have voluntarily provided

Exclusion criteria

Exclusion Criteria:

  1. Scheduled for a BR that is not listed in this protocol
  2. Requires any additional resections beyond the intestine (eg, hepatectomy, distal pancreatectomy, pancreaticoduodenectomy, gastric resection, uterine resection), or concomitant surgeries (with the exception of )
  3. Requires the formation of a stoma (ileostomy or colostomy)
  4. History of surgeries, illness, or behavior (eg, depression, psychosis) that in the opinion of the investigator might confound the study results or pose additional risk in administering the study procedures
  5. Have a functional colostomy or ileostomy
  6. Diagnosed with advanced or colon cancer (Stage IV by tumor, node, and metastasis classification)
  7. Positive coronavirus disease 2019 (COVID-19) test
  8. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection (including (HIV)), diabetes, symptomatic congestive heart failure and \< 35%, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with protocol requirements
  9. Chronic pain syndrome unrelated to the planned surgery requiring consistent management with analgesics and/or other non-pharmacologic modalities
  10. Myocardial infarction within 3 months
  11. interval > 500 msec
  12. Diabetic gastroparesis
  13. Compromised immune system, either from treatment with or other agent within 2 weeks of surgery or from immunosuppressive disease (HIV)
  14. Pregnant (identified by a positive serum pregnancy test) or lactating, or are not (no menses for at least 1 year) and are of and not using an accepted method of (surgical sterilization, intrauterine contraceptive device, oral contraceptive, diaphragm, or condom in combination with contraceptive cream, jelly, or foam or abstinence)
  15. Participated in another drug/biologic or medical device study within 30 days of surgery or will be enrolled in another investigational drug or medical device study, or any study in which active subject participation is required outside routine hospital data collection during the course of the study
  16. Illicit drug use or alcohol abuse based on medical history, or currently engaged in illicit drug use or alcohol abuse
  17. Uses of supplemental ginger, ginseng, or Zanthoxylum fruit within 72 hours before randomization
  18. Has a history of allergic reactions to ginseng, ginger, Zanthoxylum fruit, or lactose
  19. Has clinical symptoms of lactose intolerance after ingesting milk or milk-containing products (abdominal pain, flatulence, diarrhea)
  20. Unwilling or unable to comply with procedures described in this protocol or is otherwise unacceptable for enrollment in the opinion of the investigator
  21. Has a history of previous surgeries, illness (interstitial pneumonia), or behavior (depression, psychosis) that, in the opinion of the investigator, might confound the study results or pose additional risk in administering the study procedures
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
402 participants (actual)

Study arms

  • Experimental
    TU-100 15 g/day

    Subjects will receive a total daily dose of TU-100 5 g TID until hospital discharge or ≤ 10 days (whichever is earlier).

    Drug: TU-100

  • Experimental
    TU-100 7.5 g/day

    Subjects will receive a total daily dose of TU-100 2.5 g TID until hospital discharge or ≤ 10 days (whichever is earlier).

    Drug: TU-100

  • Placebo comparator
    Placebo

    Subjects will receive placebo TID until hospital discharge or ≤ 10 days (whichever is earlier).

    Drug: Placebo

Interventions

  • DrugTU-100

    Treatment with investigational product

    Also known as: Daikenchuto

  • DrugPlacebo

    Treatment with placebo product

06

What researchers measure

Primary outcomes

  1. Time to Gastrointestinal Recovery (GIR)

    Time to achieve recovery of GI motility as measured by a composite endpoint representing upper AND lower GI recovery

    Time frame: From the day after surgery (Day 1) until hospital discharge or Day 10 (whichever is earlier)

Secondary outcomes

  1. Time to GIR Responses

    Time to achieve first toleration of solid diet AND first bowel movement (Time to GI-2), time to first toleration of clear liquids, and time to absence of distension and presence of bowel sounds and flatus

    Time frame: From the day after surgery (Day 1) until hospital discharge or Day 10 (whichever is earlier)

  2. Time to Discharge

    Time at which the subject is considered ready for discharge by the investigator based solely on GI recovery (Time to ready for discharge), and time at which the investigator writes discharge order for the subject (Time to discharge order written)

    Time frame: From surgery to hospital discharge

  3. GIR Outcome Related to Length of Hospitalization (Mean)

    Mean number of days that the subject stayed in the hospital calculated based on calendar day of discharge order written

    Time frame: From surgery to hospital discharge

  4. GIR Outcome Related to Length of Hospitalization (Median)

    Median number of days that the subject stayed in the hospital calculated based on calendar day of discharge order written

    Time frame: From surgery to hospital discharge

  5. Percentage of GIR Responders

    Percentage of subjects who achieve GIR (GIR responders) by day

    Time frame: From the day after surgery (Day 1) until hospital discharge or Day 10 (whichever is earlier)

  6. POI-related Morbidity

    Primary POI that is not secondary to surgical complication, such as anastomotic leak, abscess formation, or sepsis that requires readmission within 7 days of discharge, or need for postoperative nasal gastric tube insertion to manage symptoms of POI (vomiting/retching, abdominal distension)

    Time frame: From the day after surgery to discharge follow-up visit (30 days (+ 15 days) after hospital discharge)

  7. Number of Participants With Adverse Events

    Number of patients with adverse events (AEs) observed following administration of TU-100.

    Time frame: From baseline to discharge follow-up visit (30 days (+ 15 days) after hospital discharge)

Other outcomes

  1. Subject-Reported Occurrence of Nausea

    Subjects will record the occurrence of nausea in their eDiaries on all postoperative in-hospital days.

    Time frame: From the day after surgery (Day 1) until hospital discharge or Day 10 (whichever is earlier)

  2. Subject-Reported Bothersomeness of Nausea

    Subjects who answered that they felt nauseous will record bothersomeness of nausea in their eDiaries on all postoperative in-hospital days. Bothersomeness is measured on a scale of 0-10 with 10 being the most bothersome.

    Time frame: From the day after surgery (Day 1) until hospital discharge or Day 10 (whichever is earlier)

  3. Subject-Reported Occurrence of Abdominal Bloating

    Subjects will record the occurrence of abdominal bloating in their eDiaries on all postoperative in-hospital days.

    Time frame: From the day after surgery (Day 1) until hospital discharge or Day 10 (whichever is earlier)

  4. Subject-Reported Bothersomeness of Abdominal Bloating

    Subjects who answered that they felt bloated will record bothersomeness of abdominal bloating in their eDiaries on all postoperative in-hospital days. Bothersomeness is measured on a scale of 0-10 with 10 being the most bothersome.

    Time frame: From the day after surgery (Day 1) until hospital discharge or Day 10 (whichever is earlier)

07

Results

Posted Apr 16, 2025

Participant flow

The study was carried out at 36 sites in the United States (US).

Participant flow — Overall Study
MilestoneTU-100 15 g/DayTU-100 7.5 g/DayPlacebo
Started134134134
Safety (baseline) analysis set132130130
Completed120114120
Not completed142014
Withdrew: Adverse event101
Withdrew: Lost to follow-up332
Withdrew: Physician decision010
Withdrew: Protocol violation111
Withdrew: Withdrawal by subject564
Withdrew: Subject refusal of study procedures or unable to take the study drug252
Withdrew: Did not receive the study drug244

Outcome measures

PrimaryTime to Gastrointestinal Recovery (GIR)

Time to achieve recovery of GI motility as measured by a composite endpoint representing upper AND lower GI recovery

Time frame:
From the day after surgery (Day 1) until hospital discharge or Day 10 (whichever is earlier)
Reported as:
Median · hours
Time to Gastrointestinal Recovery (GIR)
hoursTU-100 15 g/DayTU-100 7.5 g/DayPlacebo
Time to Gastrointestinal Recovery (GIR)32.6 (29.7 to 41.2)30.8 (28.1 to 35.3)33.4 (29.1 to 40.9)
Statistical analysis
  • TU-100 15 g/Day vs Placebo · Chi-squared · p = 0.767 (P-value is from the Wald Chi-Square statistic testing hypotheses of each dose of TU-100 compared with placebo: H0: hazard ratio (HR) = 1 vs. Ha: HR \> 1) · Cox proportional hazard: 0.91 · 90% CI 0.74 to 1.12Hazard ratio and confidence intervals (CIs) are derived from a Cox proportional hazard model that includes main effects for treatment and surgical approach.
  • TU-100 7.5 g/Day vs Placebo · Chi-squared · p = 0.107 (P-value is from the Wald Chi-Square statistic testing hypotheses of each dose of TU-100 compared with placebo: H0: HR = 1 vs. Ha: HR \> 1) · Cox proportional hazard: 1.17 · 90% CI 0.95 to 1.44Hazard ratio and CIs are derived from a Cox proportional hazard model that includes main effects for treatment and surgical approach.
SecondaryTime to GIR Responses

Time to achieve first toleration of solid diet AND first bowel movement (Time to GI-2), time to first toleration of clear liquids, and time to absence of distension and presence of bowel sounds and flatus

Time frame:
From the day after surgery (Day 1) until hospital discharge or Day 10 (whichever is earlier)
Reported as:
Median · hours
Time to GIR Responses
hoursTU-100 15 g/DayTU-100 7.5 g/DayPlacebo
Median Time to GI-249.4 (44.8 to 57.6)45.2 (43.5 to 46.8)47.2 (41.9 to 50.2)
Median Time to first toleration of clear liquids24.0 (22.6 to 25.5)22.5 (21.2 to 23.6)23.3 (22.6 to 24.9)
Median Time to absence of distension and presence of bowel sounds and flatus38.2 (31.3 to 41.8)40.1 (30.7 to 43.7)41.2 (37.8 to 44.6)
Statistical analysis
  • TU-100 15 g/Day vs Placebo · Chi-squared · p = 0.780 (P-value is from the Wald Chi-Square statistic testing hypotheses of each dose of TU-100 compared with placebo: H0: HR = 1 vs. Ha: HR \> 1) · Cox proportional hazard: 0.90 · 90% CI 0.71 to 1.13Hazard ratio and CIs are derived from a Cox proportional hazard model that includes main effects for treatment and surgical approach.
  • TU-100 7.5 g/Day vs Placebo · Chi-squared · p = 0.330 (P-value is from the Wald Chi-Square statistic testing hypotheses of each dose of TU-100 compared with placebo: H0: HR = 1 vs. Ha: HR \> 1) · Cox proportional hazard: 1.06 · 90% CI 0.84 to 1.34Hazard ratio and CIs are derived from a Cox proportional hazard model that includes main effects for treatment and surgical approach.
  • TU-100 15 g/Day vs Placebo · Chi-squared · p = 0.788 (P-value is from the Wald Chi-Square statistic testing hypotheses of each dose of TU-100 compared with placebo: H0: HR = 1 vs. Ha: HR \> 1) · Cox proportional hazard: 0.90 · 90% CI 0.73 to 1.11Hazard ratio and CIs are derived from a Cox proportional hazard model that includes main effects for treatment and surgical approach.
  • TU-100 7.5 g/Day vs Placebo · Chi-squared · p = 0.055 (P-value is from the Wald Chi-Square statistic testing hypotheses of each dose of TU-100 compared with placebo: H0: HR = 1 vs. Ha: HR \> 1) · Cox proportional hazard: 1.22 · 90% CI 0.99 to 1.51Hazard ratio and CIs are derived from a Cox proportional hazard model that includes main effects for treatment and surgical approach.
  • TU-100 15 g/Day vs Placebo · Chi-squared · p = 0.306 (P-value is from the Wald Chi-Square statistic testing hypotheses of each dose of TU-100 compared with placebo: H0: HR = 1 vs. Ha: HR \> 1) · Cox proportional hazard: 1.07 · 90% CI 0.86 to 1.32Hazard ratio and CIs are derived from a Cox proportional hazard model that includes main effects for treatment and surgical approach.
  • TU-100 7.5 g/Day vs Placebo · Chi-squared · p = 0.243 (P-value is from the Wald Chi-Square statistic testing hypotheses of each dose of TU-100 compared with placebo: H0: HR = 1 vs. Ha: HR \> 1) · Cox proportional hazard: 1.09 · 90% CI 0.88 to 1.35Hazard ratio and CIs are derived from a Cox proportional hazard model that includes main effects for treatment and surgical approach.
SecondaryTime to Discharge

Time at which the subject is considered ready for discharge by the investigator based solely on GI recovery (Time to ready for discharge), and time at which the investigator writes discharge order for the subject (Time to discharge order written)

Time frame:
From surgery to hospital discharge
Reported as:
Median · hours
Time to Discharge
hoursTU-100 15 g/DayTU-100 7.5 g/DayPlacebo
Time to ready for discharge56.1 (49.4 to 66.3)52.2 (48.4 to 59.8)66.1 (52.4 to 68.2)
Time to discharge order written64.3 (50.5 to 67.8)58.1 (51.1 to 65.7)66.6 (63.5 to 69.1)
Statistical analysis
  • TU-100 15 g/Day vs Placebo · Chi-squared · p = 0.489 (P-value is from the Wald Chi-Square statistic testing hypotheses of each dose of TU-100 compared with placebo: H0: HR = 1 vs. Ha: HR \> 1) · Cox proportional hazard: 1.00 · 90% CI 0.81 to 1.24Hazard ratio and CIs are derived from a Cox proportional hazard model that includes main effects for treatment and surgical approach.
  • TU-100 7.5 g/Day vs Placebo · Chi-squared · p = 0.138 (P-value is from the Wald Chi-Square statistic testing hypotheses of each dose of TU-100 compared with placebo: H0: HR = 1 vs. Ha: HR \> 1) · Cox proportional hazard: 1.15 · 90% CI 0.93 to 1.42Hazard ratio and CIs are derived from a Cox proportional hazard model that includes main effects for treatment and surgical approach.
  • TU-100 15 g/Day vs Placebo · Chi-squared · p = 0.473 (P-value is from the Wald Chi-Square statistic testing hypotheses of each dose of TU-100 compared with placebo: H0: HR = 1 vs. Ha: HR \> 1) · Cox proportional hazard: 1.01 · 90% CI 0.82 to 1.24Hazard ratio and CIs are derived from a Cox proportional hazard model that includes main effects for treatment and surgical approach.
  • TU-100 7.5 g/Day vs Placebo · Chi-squared · p = 0.045 (P-value is from the Wald Chi-Square statistic testing hypotheses of each dose of TU-100 compared with placebo: H0: HR = 1 vs. Ha: HR \> 1) · Cox proportional hazard: 1.24 · 90% CI 1.01 to 1.53Hazard ratio and CIs are derived from a Cox proportional hazard model that includes main effects for treatment and surgical approach.
SecondaryGIR Outcome Related to Length of Hospitalization (Mean)

Mean number of days that the subject stayed in the hospital calculated based on calendar day of discharge order written

Time frame:
From surgery to hospital discharge
Reported as:
Mean · days
GIR Outcome Related to Length of Hospitalization (Mean)
daysTU-100 15 g/DayTU-100 7.5 g/DayPlacebo
GIR Outcome Related to Length of Hospitalization (Mean)3.3 ± 3.072.7 ± 1.303.3 ± 3.00
Statistical analysis
  • TU-100 15 g/Day vs Placebo · t-test, 2 sided · p = 0.923 (P-value is from two-sample t-test comparing TU-100 15 g/day treatment group versus placebo.)
  • TU-100 7.5 g/Day vs Placebo · t-test, 2 sided · p = 0.039 (P-value is from two-sample t-test comparing TU-100 7.5 g/day treatment group versus placebo.)
SecondaryGIR Outcome Related to Length of Hospitalization (Median)

Median number of days that the subject stayed in the hospital calculated based on calendar day of discharge order written

Time frame:
From surgery to hospital discharge
Reported as:
Median · days
GIR Outcome Related to Length of Hospitalization (Median)
daysTU-100 15 g/DayTU-100 7.5 g/DayPlacebo
GIR Outcome Related to Length of Hospitalization (Median)3 (1 to 28)2 (1 to 7)3 (1 to 29)
SecondaryPercentage of GIR Responders

Percentage of subjects who achieve GIR (GIR responders) by day

Time frame:
From the day after surgery (Day 1) until hospital discharge or Day 10 (whichever is earlier)
Reported as:
Number · percentage of subjects
Percentage of GIR Responders
percentage of subjectsTU-100 15 g/DayTU-100 7.5 g/DayPlacebo
Day 120.522.724.6
Day 247.055.542.3
Day 318.214.120.8
Day 43.81.66.2
Statistical analysis
  • TU-100 15 g/Day vs Placebo · Regression, Logistic · p = 0.434 (p value is assessing the null hypothesis that the odds ratio is equal to 1.) · Odds ratio (or): 0.79 · 95% CI 0.44 to 1.42Responder status is analyzed using logistic regression with GIR response as the dependent variable; treatment and surgical approach (open, laparoscopic) as covariates.
  • TU-100 7.5 g/Day vs Placebo · Regression, Logistic · p = 0.710 (p value is assessing the null hypothesis that the odds ratio is equal to 1.) · Odds ratio (or): 0.90 · 95% CI 0.51 to 1.59Responder status is analyzed using logistic regression with GIR response as the dependent variable; treatment and surgical approach (open, laparoscopic) as covariates.
  • TU-100 15 g/Day vs Placebo · Chi-squared · p = 0.410 (p value is assessing the null hypothesis that the odds ratio is equal to 1.) · Odds ratio (or): 1.23 · 95% CI 0.75 to 2.02Responder status is analyzed using logistic regression with GIR response as the dependent variable; treatment and surgical approach (open, laparoscopic) as covariates.
  • TU-100 7.5 g/Day vs Placebo · Regression, Logistic · p = 0.037 (p value is assessing the null hypothesis that the odds ratio is equal to 1.) · Odds ratio (or): 1.70 · 95% CI 1.03 to 2.81Responder status is analyzed using logistic regression with GIR response as the dependent variable; treatment and surgical approach (open, laparoscopic) as covariates.
  • TU-100 15 g/Day vs Placebo · Regression, Logistic · p = 0.579 (p value is assessing the null hypothesis that the odds ratio is equal to 1.) · Odds ratio (or): 0.84 · 95% CI 0.46 to 1.55Responder status is analyzed using logistic regression with GIR response as the dependent variable; treatment and surgical approach (open, laparoscopic) as covariates.
  • TU-100 7.5 g/Day vs Placebo · Regression, Logistic · p = 0.167 (p value is assessing the null hypothesis that the odds ratio is equal to 1.) · Odds ratio (or): 0.63 · 95% CI 0.33 to 1.21
  • TU-100 15 g/Day vs Placebo · Regression, Logistic · p = 0.400 (p value is assessing the null hypothesis that the odds ratio is equal to 1.) · Odds ratio (or): 0.63 · 95% CI 0.21 to 1.86Responder status is analyzed using logistic regression with GIR response as the dependent variable; treatment and surgical approach (open, laparoscopic) as covariates.
  • TU-100 7.5 g/Day vs Placebo · Regression, Logistic · p = 0.083 · Odds ratio (or): 0.28 · 95% CI 0.07 to 1.18Responder status is analyzed using logistic regression with GIR response as the dependent variable; treatment and surgical approach (open, laparoscopic) as covariates.
SecondaryPOI-related Morbidity

Primary POI that is not secondary to surgical complication, such as anastomotic leak, abscess formation, or sepsis that requires readmission within 7 days of discharge, or need for postoperative nasal gastric tube insertion to manage symptoms of POI (vomiting/retching, abdominal distension)

Time frame:
From the day after surgery to discharge follow-up visit (30 days (+ 15 days) after hospital discharge)
Reported as:
Count of participants · Participants
POI-related Morbidity
ParticipantsTU-100 15 g/DayTU-100 7.5 g/DayPlacebo
POI-related Morbidity755
Statistical analysis
  • TU-100 15 g/Day vs Placebo · Regression, Logistic · p = 0.621 (p value is assessing the null hypothesis that the odds ratio is equal to 1.) · Odds ratio (or): 1.33 · 95% CI 0.43 to 4.14POI-related Morbidity status is analyzed using logistic regression with POI-related morbidity as the dependent variable; treatment and surgical approach (open, laparoscopic) as covariates.
  • TU-100 7.5 g/Day vs Placebo · Regression, Logistic · p = 0.962 (p value is assessing the null hypothesis that the odds ratio is equal to 1.) · Odds ratio (or): 1.03 · 95% CI 0.31 to 3.46POI-related Morbidity status is analyzed using logistic regression with POI-related morbidity as the dependent variable; treatment and surgical approach (open, laparoscopic) as covariates.
SecondaryNumber of Participants With Adverse Events

Number of patients with adverse events (AEs) observed following administration of TU-100.

Time frame:
From baseline to discharge follow-up visit (30 days (+ 15 days) after hospital discharge)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events
ParticipantsTU-100 15 g/DayTU-100 7.5 g/DayPlacebo
Number of Participants With Adverse Events787381
Other pre-specifiedSubject-Reported Occurrence of Nausea

Subjects will record the occurrence of nausea in their eDiaries on all postoperative in-hospital days.

Time frame:
From the day after surgery (Day 1) until hospital discharge or Day 10 (whichever is earlier)
Reported as:
Count of participants · Participants
Subject-Reported Occurrence of Nausea
ParticipantsTU-100 15 g/DayTU-100 7.5 g/DayPlacebo
Day 1393735
Day 2261625
Day 310911
Day 4366
Statistical analysis
  • TU-100 15 g/Day vs Placebo · Regression, Logistic · p = 0.604 (p value is assessing the null hypothesis that the odds ratio is equal to 1.) · Odds ratio (or): 1.16 · 95% CI 0.66 to 2.05Subject-reported (eDiary) - Nausea status is analyzed using logistic regression with Subject-reported (eDiary) - Nausea as the dependent variable; treatment and surgical approach (open, laparoscopic) as covariates.
  • TU-100 7.5 g/Day vs Placebo · Regression, Logistic · p = 0.693 (p value is assessing the null hypothesis that the odds ratio is equal to 1.) · Odds ratio (or): 1.12 · 95% CI 0.63 to 1.99Subject-reported (eDiary) - Nausea status is analyzed using logistic regression with Subject-reported (eDiary) - Nausea as the dependent variable; treatment and surgical approach (open, laparoscopic) as covariates.
  • TU-100 15 g/Day vs Placebo · Regression, Logistic · p = 0.122 (p value is assessing the null hypothesis that the odds ratio is equal to 1.) · Odds ratio (or): 1.80 · 95% CI 0.85 to 3.78Subject-reported (eDiary) - Nausea status is analyzed using logistic regression with Subject-reported (eDiary) - Nausea as the dependent variable; treatment and surgical approach (open, laparoscopic) as covariates.
  • TU-100 7.5 g/Day vs Placebo · Regression, Logistic · p = 0.518 (p value is assessing the null hypothesis that the odds ratio is equal to 1.) · Odds ratio (or): 0.78 · 95% CI 0.36 to 1.67Subject-reported (eDiary) - Nausea status is analyzed using logistic regression with Subject-reported (eDiary) - Nausea as the dependent variable; treatment and surgical approach (open, laparoscopic) as covariates.
  • TU-100 15 g/Day vs Placebo · Regression, Logistic · p = 0.528 (p value is assessing the null hypothesis that the odds ratio is equal to 1.) · Odds ratio (or): 1.45 · 95% CI 0.46 to 4.53Subject-reported (eDiary) - Nausea status is analyzed using logistic regression with Subject-reported (eDiary) - Nausea as the dependent variable; treatment and surgical approach (open, laparoscopic) as covariates.
  • TU-100 7.5 g/Day vs Placebo · Regression, Logistic · p = 0.689 (p value is assessing the null hypothesis that the odds ratio is equal to 1.) · Odds ratio (or): 1.27 · 95% CI 0.40 to 4.07Subject-reported (eDiary) - Nausea status is analyzed using logistic regression with Subject-reported (eDiary) - Nausea as the dependent variable; treatment and surgical approach (open, laparoscopic) as covariates.
  • TU-100 15 g/Day vs Placebo · Regression, Logistic · p = 0.653 (p value is assessing the null hypothesis that the odds ratio is equal to 1.) · Odds ratio (or): 0.68 · 95% CI 0.12 to 3.70Subject-reported (eDiary) - Nausea status is analyzed using logistic regression with Subject-reported (eDiary) - Nausea as the dependent variable; treatment and surgical approach (open, laparoscopic) as covariates.
  • TU-100 7.5 g/Day vs Placebo · Regression, Logistic · p = 0.452 (p value is assessing the null hypothesis that the odds ratio is equal to 1.) · Odds ratio (or): 1.85 · 95% CI 0.37 to 9.25Subject-reported (eDiary) - Nausea status is analyzed using logistic regression with Subject-reported (eDiary) - Nausea as the dependent variable; treatment and surgical approach (open, laparoscopic) as covariates.
Other pre-specifiedSubject-Reported Bothersomeness of Nausea

Subjects who answered that they felt nauseous will record bothersomeness of nausea in their eDiaries on all postoperative in-hospital days. Bothersomeness is measured on a scale of 0-10 with 10 being the most bothersome.

Time frame:
From the day after surgery (Day 1) until hospital discharge or Day 10 (whichever is earlier)
Reported as:
Least squares mean · score of nausea bothersomeness
Subject-Reported Bothersomeness of Nausea
score of nausea bothersomenessTU-100 15 g/DayTU-100 7.5 g/DayPlacebo
Day 15.5 ± 0.466.0 ± 0.476.1 ± 0.48
Day 26.0 ± 0.534.7 ± 0.665.8 ± 0.54
Day 36.7 ± 0.785.5 ± 0.866.5 ± 0.79
Statistical analysis
  • TU-100 15 g/Day vs Placebo · Mixed Models Analysis · p = 0.359 · Mean difference (final values): -0.6 · 95% CI -1.8 to 0.6
  • TU-100 7.5 g/Day vs Placebo · Mixed Models Analysis · p = 0.907 · Mean difference (final values): -0.1 · 95% CI -1.3 to 1.2
  • TU-100 15 g/Day vs Placebo · Mixed Models Analysis · p = 0.856 · Mean difference (final values): 0.1 · 95% CI -1.3 to 1.6
  • TU-100 7.5 g/Day vs Placebo · Mixed Models Analysis · p = 0.180 · Mean difference (final values): -1.1 · 95% CI -2.7 to 0.5
  • TU-100 15 g/Day vs Placebo · Mixed Models Analysis · p = 0.814 · Mean difference (final values): 0.3 · 95% CI -1.9 to 2.4
  • TU-100 7.5 g/Day vs Placebo · Mixed Models Analysis · p = 0.409 · Mean difference (final values): -1.0 · 95% CI -3.2 to 1.3
Other pre-specifiedSubject-Reported Occurrence of Abdominal Bloating

Subjects will record the occurrence of abdominal bloating in their eDiaries on all postoperative in-hospital days.

Time frame:
From the day after surgery (Day 1) until hospital discharge or Day 10 (whichever is earlier)
Reported as:
Count of participants · Participants
Subject-Reported Occurrence of Abdominal Bloating
ParticipantsTU-100 15 g/DayTU-100 7.5 g/DayPlacebo
Day 1616766
Day 2303049
Day 3141321
Day 46711
Statistical analysis
  • TU-100 15 g/Day vs Placebo · Regression, Logistic · p = 0.430 (p value is assessing the null hypothesis that the odds ratio is equal to 1.) · Odds ratio (or): 0.80 · 95% CI 0.46 to 1.40Subject-reported (eDiary) - Abdominal Bloating status is analyzed using logistic regression with Subject-reported (eDiary) - Abdominal Bloating as the dependent variable; treatment and surgical approach (open, laparoscopic) as covariates.
  • TU-100 7.5 g/Day vs Placebo · Regression, Logistic · p = 0.739 (p value is assessing the null hypothesis that the odds ratio is equal to 1.) · Odds ratio (or): 1.10 · 95% CI 0.62 to 1.96Subject-reported (eDiary) - Abdominal Bloating status is analyzed using logistic regression with Subject-reported (eDiary) - Abdominal Bloating as the dependent variable; treatment and surgical approach (open, laparoscopic) as covariates.
  • TU-100 15 g/Day vs Placebo · Regression, Logistic · p = 0.130 (p value is assessing the null hypothesis that the odds ratio is equal to 1.) · Odds ratio (or): 0.54 · 95% CI 0.25 to 1.20Subject-reported (eDiary) - Abdominal Bloating status is analyzed using logistic regression with Subject-reported (eDiary) - Abdominal Bloating as the dependent variable; treatment and surgical approach (open, laparoscopic) as covariates.
  • TU-100 7.5 g/Day vs Placebo · Regression, Logistic · p = 0.099 (p value is assessing the null hypothesis that the odds ratio is equal to 1.) · Odds ratio (or): 0.52 · 95% CI 0.24 to 1.13Subject-reported (eDiary) - Abdominal Bloating status is analyzed using logistic regression with Subject-reported (eDiary) - Abdominal Bloating as the dependent variable; treatment and surgical approach (open, laparoscopic) as covariates.
  • TU-100 15 g/Day vs Placebo · Regression, Logistic · p = 0.686 (p value is assessing the null hypothesis that the odds ratio is equal to 1.) · Odds ratio (or): 0.78 · 95% CI 0.23 to 2.63Subject-reported (eDiary) - Abdominal Bloating status is analyzed using logistic regression with Subject-reported (eDiary) - Abdominal Bloating as the dependent variable; treatment and surgical approach (open, laparoscopic) as covariates.
  • TU-100 7.5 g/Day vs Placebo · Regression, Logistic · p = 0.644 (p value is assessing the null hypothesis that the odds ratio is equal to 1.) · Odds ratio (or): 0.75 · 95% CI 0.22 to 2.56Subject-reported (eDiary) - Abdominal Bloating status is analyzed using logistic regression with Subject-reported (eDiary) - Abdominal Bloating as the dependent variable; treatment and surgical approach (open, laparoscopic) as covariates.
  • TU-100 15 g/Day vs Placebo · Regression, Logistic · p = 0.498 (p value is assessing the null hypothesis that the odds ratio is equal to 1.) · Odds ratio (or): 0.54 · 95% CI 0.09 to 3.18Subject-reported (eDiary) - Abdominal Bloating status is analyzed using logistic regression with Subject-reported (eDiary) - Abdominal Bloating as the dependent variable; treatment and surgical approach (open, laparoscopic) as covariates.
  • TU-100 7.5 g/Day vs Placebo · Regression, Logistic · p = 0.700 (p value is assessing the null hypothesis that the odds ratio is equal to 1.) · Odds ratio (or): 0.71 · 95% CI 0.12 to 4.05Subject-reported (eDiary) - Abdominal Bloating status is analyzed using logistic regression with Subject-reported (eDiary) - Abdominal Bloating as the dependent variable; treatment and surgical approach (open, laparoscopic) as covariates.
Other pre-specifiedSubject-Reported Bothersomeness of Abdominal Bloating

Subjects who answered that they felt bloated will record bothersomeness of abdominal bloating in their eDiaries on all postoperative in-hospital days. Bothersomeness is measured on a scale of 0-10 with 10 being the most bothersome.

Time frame:
From the day after surgery (Day 1) until hospital discharge or Day 10 (whichever is earlier)
Reported as:
Least squares mean · score of bloating bothersomeness
Subject-Reported Bothersomeness of Abdominal Bloating
score of bloating bothersomenessTU-100 15 g/DayTU-100 7.5 g/DayPlacebo
Day 15.2 ± 0.344.2 ± 0.335.2 ± 0.33
Day 25.6 ± 0.444.4 ± 0.434.6 ± 0.36
Day 35.6 ± 0.624.3 ± 0.645.0 ± 0.51
Statistical analysis
  • TU-100 15 g/Day vs Placebo · Mixed Models Analysis · p = 0.919 · Mean difference (final values): 0.0 · 95% CI -0.9 to 0.8
  • TU-100 7.5 g/Day vs Placebo · Mixed Models Analysis · p = 0.016 · Mean difference (final values): -1.0 · 95% CI -1.8 to -0.2
  • TU-100 15 g/Day vs Placebo · Mixed Models Analysis · p = 0.064 · Mean difference (final values): 1.0 · 95% CI -0.1 to 2.0
  • TU-100 7.5 g/Day vs Placebo · Mixed Models Analysis · p = 0.683 · Mean difference (final values): -0.2 · 95% CI -1.3 to 0.8
  • TU-100 15 g/Day vs Placebo · Mixed Models Analysis · p = 0.462 · Mean difference (final values): 0.6 · 95% CI -1.0 to 2.1
  • TU-100 7.5 g/Day vs Placebo · Mixed Models Analysis · p = 0.343 · Mean difference (final values): -0.8 · 95% CI -2.3 to 0.8

Adverse events

Collected over From baseline to discharge follow-up visit (30 days (+ 15 days) after hospital discharge). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
TU-100 15 g/Day0/132 (0%)19/132 (14.4%)29/132 (22%)
TU-100 7.5 g/Day0/130 (0%)14/130 (10.8%)39/130 (30%)
Placebo0/130 (0%)9/130 (6.9%)39/130 (30%)
Most frequent serious events
Showing 10 of 29
Most frequent serious events
EventTU-100 15 g/DayTU-100 7.5 g/DayPlacebo
Postoperative ileusInjury, poisoning and procedural complications8/1323/1303/130
HaematocheziaGastrointestinal disorders1/1322/1301/130
Small intestinal obstructionGastrointestinal disorders0/1322/1301/130
Clostridium difficile colitisInfections and infestations2/1321/1300/130
Anastomotic leakInjury, poisoning and procedural complications0/1321/1301/130
SepsisInfections and infestations1/1321/1300/130
Abdominal infectionInfections and infestations0/1320/1301/130
Clostridium difficile infectionInfections and infestations0/1321/1300/130
Pelvic abscessInfections and infestations0/1321/1301/130
DiarrhoeaGastrointestinal disorders1/1321/1300/130
Most frequent other events
Most frequent other events
EventTU-100 15 g/DayTU-100 7.5 g/DayPlacebo
NauseaGastrointestinal disorders16/13220/13025/130
VomitingGastrointestinal disorders10/13210/1308/130
ConstipationGastrointestinal disorders2/1328/1307/130
DiarrhoeaGastrointestinal disorders7/1325/1308/130
Abdominal distensionGastrointestinal disorders5/1327/1305/130

Baseline characteristics

Baseline analysis population includes all randomized subjects who were administered at least one dose of study treatment (safety analysis set).

Age, Continuous
Age, Continuous(years)TU-100 15 g/DayTU-100 7.5 g/DayPlaceboTotal
Mean57.7 ± 13.1458.3 ± 13.0758.5 ± 12.0958.2 ± 12.75
Sex: Female, Male
Sex: Female, Male(Participants)TU-100 15 g/DayTU-100 7.5 g/DayPlaceboTotal
Female686972209
Male646158183
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)TU-100 15 g/DayTU-100 7.5 g/DayPlaceboTotal
Hispanic or Latino591327
Not Hispanic or Latino125121116362
Unknown or Not Reported2013
Race (NIH/OMB)
Race (NIH/OMB)(Participants)TU-100 15 g/DayTU-100 7.5 g/DayPlaceboTotal
American Indian or Alaska Native0000
Asian61310
Native Hawaiian or Other Pacific Islander0000
Black or African American1361029
White109118110337
More than one race0101
Unknown or Not Reported44715
BMI
BMI(kg/m2)TU-100 15 g/DayTU-100 7.5 g/DayPlaceboTotal
Mean28.43 ± 6.24229.46 ± 5.78828.97 ± 5.64928.95 ± 5.900
08

Study locations

36 sites
  • Florence Site
    Florence, Alabama 35630, United States
  • Gilbert Site
    Gilbert, Arizona 85234, United States
  • Little Rock Site
    Little Rock, Arkansas 72205, United States
  • Duarte Site
    Duarte, California 91010, United States
  • Los Angeles Site #1
    Los Angeles, California 90033, United States
  • Los Angeles Site #2
    Los Angeles, California 90048, United States
  • Palo Alto Site
    Palo Alto, California 94304, United States
  • Sacramento Site
    Sacramento, California 95817, United States
  • Danbury Site
    Danbury, Connecticut 06810, United States
  • Clearwater Site
    Clearwater, Florida 33756, United States
  • Orlando Site
    Orlando, Florida 32803, United States
  • Tampa Site
    Tampa, Florida 33606, United States
  • Weston Site
    Weston, Florida 33331, United States
  • Chicago Site #2
    Chicago, Illinois 60612, United States
  • Chicago Site #1
    Chicago, Illinois 60637, United States
  • Urbana Site
    Urbana, Illinois 61801, United States
  • Lexington Site
    Lexington, Kentucky 40536, United States
  • Metairie Site
    Metairie, Louisiana 70006, United States
  • Boston Site #1
    Boston, Massachusetts 02115, United States
  • Detroit Site
    Detroit, Michigan 48201, United States
  • St. Louis Site
    Saint Louis, Missouri 63110, United States
  • Newark Site
    Newark, New Jersey 07103, United States
  • Mineola Site
    Mineola, New York 11501, United States
  • New York Site
    New York, New York 10065, United States
  • Stony Brook Site
    Stony Brook, New York 11794, United States
  • Cleveland Site #2
    Cleveland, Ohio 44111, United States
  • Cleveland Site #1
    Cleveland, Ohio 44195, United States
  • Philadelphia Site #2
    Philadelphia, Pennsylvania 19140, United States
  • Pittsburgh Site
    Pittsburgh, Pennsylvania 15212, United States
  • Charleston Site
    Charleston, South Carolina 29425, United States
  • Memphis Site
    Memphis, Tennessee 38120, United States
  • Dallas Site
    Dallas, Texas 75246, United States
  • Fort Worth Site
    Fort Worth, Texas 76104, United States
  • Salt Lake City Site
    Salt Lake City, Utah 84132, United States
  • Roanoke Site
    Roanoke, Virginia 24014, United States
  • Milwaukee Site
    Milwaukee, Wisconsin 53226, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2021 to primary completion in Mar 2024, 31 months.

Results were first posted in Apr 2025, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 29, 2021
First posted
Feb 8, 2021
StartActual
Jul 29, 2021
Primary completionActual
Mar 25, 2024
CompletionActual
May 1, 2024
Results first posted
Apr 16, 2025
Last update
Apr 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04742907
Lead sponsor
Tsumura USA
Responsible party
Sponsor
First posted
Feb 8, 2021
Start date
Jul 29, 2021
Primary completion
Mar 25, 2024
Completion
May 1, 2024
Results posted
Apr 16, 2025
Last update
Apr 16, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tu-100

Start the discussion